Out Fox The $treet

Update - Dec. 19 The market remains absurd at the lows. $ CURLF  and other $ MSOS  weren't priced for the SAFE approval and don't even need the bill. People selling don't know what they are doing. -A long-shot attempt by lawmakers to get the SAFE Banking Act passed by including it in the omnibus spending bill has failed, Marijuana Moment reported. -Most of the major multi-state operators fell by double digits late in Monday's trading session when the news broke. -While the legislation could still pass as a stand-alone bill in the lame duck session, with only a couple of weeks until the new Congress is sworn in, that prospect is highly unlikely. -There is hope that the legislation will have legs in 2023. Rep. Patrick McHenry (R-N.C.), the incoming chair of the House Committee, recently told Punchbowl News that while he is opposed to the legislation, he has "pledged to have an open process" in discussing it. Update - Dec. 16 Schumer continues working on  SAFE+ a...

  Senate Democrats finally introduce a cannabis bill with the potential for approval. Curaleaf continues poised to benefit from recreational cannabis legalization in the tri-state area adding ~$10 billion in additional revenues to the market. The stock remains cheap at just 8x conservative '23 adjusted EBITDA targets. This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   The Senate Democrats finally releasing a bill gives some slim hopes of Federal legislation on cannabis.  Curaleaf Holdings  ( OTCPK:CURLF ) stands to benefit from such legislation while still holding the wild card of significant growth from Northeast  markets without Federal approval. My  investment thesis  remains ultra bullish on the stock after the inexplicable dip to $5 recently. Read the full article on Seeking Alpha  Disclosure: No position mentioned. Please review the disclaimer page for more det...

  Curaleaf is forecast to report a massive Q3'21 with adjusted EBITDA profits topping $100 million for the first time. The company has up to 5 Northeast states opening up recreational cannabis sales by 2023, adding at least $11 billion to the market opportunity. The average analyst price target predicts 125% upside in the stock. The stock only trades at only 12x '22 base EBITDA targets. Looking for a helping hand in the market? Members of Out Fox The Street get exclusive ideas and guidance to navigate any climate.  Learn More » As the U.S. MSOs (multi-state operators) continue to slump, the market needs to remember these companies are the true market leaders.  Curaleaf  ( OTCPK:CURLF ) is looking towards some massive quarters down the road and the market will eventually catch on. My  investment thesis  remains Bullish on this "Big Cannabis" play. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer p...

Curaleaf is on a path to lead the cannabis market in revenues. The stock remains far under the radar of investors based on followers on financial websites. The stock is cheaply priced at 2-3x forward revenue estimates. A few months after announcing the big Grassroots merger,  Curaleaf Holdings  ( OTCPK:CURLF ) has traded relatively flat. Despite the company being in the process of becoming a leader in the global cannabis industry, the stock is relatively unknown and unfollowed. My  investment thesis  remains bullish on the stock and the general multi-state operators (MSOs) in the U.S. Read the full article on Seeking Alpha.  More commentary - Out Fox The $treet - September 26 Disclosure: No position. Please review the disclaimer page for more details. 

Aurora Cannabis continues rallying after another premium deal. The company not providing financial details of acquisitions and quarterly operating losses in press releases is a major red flag. Momentum traders on Robinhood are very bullish on the stock. Aurora Cannabis has the potential to improve the investment picture via more detailed financials on the FQ2 report with more details of the path to an EBITDA-positive FQ4. The company is still making the wrong deals. My  previous research  has been critical of  Aurora Cannabis  ( ACB ) making too many deals and aggressively expanding cannabis production into the inevitable sector crash. Instead of making strategic partnerships and looking to sell production facilities at premium prices, the company continues down the path of massive shareholder dilution that will eventually wreck the stock. Read the full article on Seeking Alpha.